The Cocoon project, set up in Tayside, Scotland seeks to address the high rate of drug-related deaths in the area.
The project delivers point-of-care diagnosis of HCV in needle exchange sites, while also integrating services which typically require travel to alternate NHS sites to reduce the burden of multiple visits and different providers. The result is a ‘one-stop’ holistic care bundle which seeks to address the inequity of access experienced by PWUD by increasing their engagement through services tailored to their specific needs.
Measuring the impact of the recommendations of the London Joint Working Group on Substance Use and Hepatitis C - learning from the pilots
Download
In 2011 the London Joint Working Group published 'Tackling the Problem of Hepatitis C, Substance Misuse and Health Inequalities: a Consensus for London'. The document set out a number of recommendations to improve the integration of services in London for people with hepatitis C and a history of using drugs. In 2013 the group aimed to assess the impact of its recommendations by setting up a pilot project in four London boroughs. By establishing goals and enabling the pilot teams to set out their own plans to achieve them, it was hoped that it would be possible to identify specific measures that most effectively led to increased rates of testing and referral, as well as identifying gaps and blocks in the care pathway.
This report provides an overview of the impact of the LJWG's recommendations, and higlights the need for a better understanding of funding streams in the new commissioning environment; improved data collection, and strategic leadership to ensure a co-ordinated approach to monitoring and improving hepatitis C care pathways for people with a history of drug use.
This report provides an overview of the impact of the LJWG's recommendations, and higlights the need for a better understanding of funding streams in the new commissioning environment; improved data collection, and strategic leadership to ensure a co-ordinated approach to monitoring and improving hepatitis C care pathways for people with a history of drug use.
